Lexaria Bioscience (LEXX) Short Interest Ratio & Short Volume

Short interest is the volume of Lexaria Bioscience shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 157,500 shares of LEXX short. 1.40% of Lexaria Bioscience's shares are currently sold short. Learn More on Lexaria Bioscience's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.40% of Lexaria Bioscience's floating shares are currently sold short.

Lexaria Bioscience saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 157,500 shares, a decline of 38.8% from the previous total of 257,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lexaria Bioscience currently has issued a total of 12,890,000 shares. Some of Lexaria Bioscience's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lexaria Bioscience currently has a public float of 11,240,000 shares.

1.40% of Lexaria Bioscience's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lexaria Bioscience: Greenwich LifeSciences, Inc. (3.03%), Lifecore Biomedical, Inc. (6.86%), Abeona Therapeutics Inc (7.76%), Alimera Sciences, Inc. (0.20%), Rigel Pharmaceuticals, Inc. (3.22%), Veru Inc. (8.65%), Sagimet Biosciences Inc. (10.29%), Context Therapeutics Inc. (1.38%), Cartesian Therapeutics, Inc. (13.69%), ProQR Therapeutics (0.45%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling LEXX is an investing strategy that aims to generate trading profit from Lexaria Bioscience as its price is falling. LEXX shares are trading up $0.41 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lexaria Bioscience occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LEXX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LEXX, twice per month. The most recent reporting period available is May, 15 2024.